Healthcare >> CEO Interviews >> January 10, 2001
DR. PAUL KELLY is a co-founder and has served as of Gemini Genomics Plc
Chief Executive Officer since January 1997. He originally trained in
medicine at the University of New South Wales, Sydney, Australia, where
he received his MBBS in 1983. He then trained as a physician,
specializing in endocrinology, at St. Vincent's Hospital, Sydney, and
received his Fellowship of the Royal Australian College of Physicians in
1990. He was awarded a Doctor of Medicine Degree from the University of
South Wales in 1990, with his thesis on the genetics of osteoporosis.
Dr. Kelly has held academic positions at the Faculty of Medicine of the
University of New South Wales and has published over 80 scientific
papers and has contributed to a number of books and other publications,
particularly in the genetic epidemiology of osteoporosis, obesity and
insulin resistance syndrome. He is the co-inventor of a patent relating
to vitamin-D receptor alleles and osteoporosis susceptibility. Profile
Dr. Kelly: Gemini Genomics was incorporated in late 1995 and was really
born out of experience in the medical application of clinical
